NCT03006003

Osteoporosis Treatment in Post-menopausal Women

The Assessment of Osteoporosis Treatment in Post-menopausal Women

• Status: Unknown
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 500 (estimated)
• Sponsor: Taichung Veterans General Hospital · Academic / Other
• Sex: Female
• Age: 20 Years
• Healthy volunteers: Not accepted

Summary

The study will be conducted to assess the depressive symptoms and related markers in the postmenopausal female after anti-osteoporosis treatment.

Detailed description

Fracture is one of the important complications in female. Osteoporosis should be treated in postmenopausal female due to high risk of fracture. Recently, there have been many classes of medications developed for preventing bone loss. Raloxifene, an oral form of anti-osteoporosis medication, has been reported to improved central nervous disorders. Therefore, this study is designed to assess the depressive symptoms and related markers in the postmenopausal female after anti-osteoporosis treatment.

Conditions

• Depressive Syndrome

Interventions

Type	Name	Description
DRUG	Raloxifene	Raloxifene tratment more than 4 weeks
DRUG	Alendronate	Alendronic acid 70mg with Colecalciferol 70mcg

Timeline

• Start date: 2017-01-01
• Primary completion: 2021-12-01
• Completion: 2021-12-01
• First posted: 2016-12-30
• Last updated: 2019-01-14

Locations

2 sites across 1 country: Taiwan